Li Kang Biomedical Co (6242) Fair Value & Analysis
Consumer Cyclical · TW · Market cap 1.1B TWD
Fair value as of: Jul 21, 2026
From 14 valuation models · updated 20 days ago
Share price −5.0% over the past month.
Below-average quality, screening 22% undervalued on our models.
What matters now
- Solid quality (45/100) at a price below fair value, the discount is the argument here, not the business quality.
- A fairly wide model range (29.31 TWD to 54.43 TWD) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 21, 2026.
How to read this chart
60‑month range 22.60 TWD – 56.95 TWD · fair‑value band 29.31 TWD – 54.43 TWD · the 34.30 TWD price screens below the 41.87 TWD fair value. Dashed = 300-day average. As of Jul 21, 2026.
Analysis
Li Kang Biomedical Co (6242) currently trades at 34.30 TWD, while our model-based Fair Value estimate is 41.87 TWD, implying the stock looks roughly 22.1% undervalued today. The Quality Score stands at 45/100 (below-average quality), in the Consumer Cyclical sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, Li Kang Biomedical Co generated revenue of 576M TWD at a net margin of 13.5%. Revenue declined 9.8% year over year. It earns a return on equity of 8.9%. Net debt stands at 49.4M TWD. Fundamentals as of Jul 21, 2026
Our scenario range runs from 29.31 TWD (bear case) to 54.43 TWD (bull case); at 34.30 TWD, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 22% below its 52-week high, currently below its 200-day average. For context, the median of 10 Consumer Cyclical peers we cover trades at -16% fair-value upside, at 22%, 6242 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 14 models by family
Widest divergence: Multiples (44.80 TWD) versus Asset-Based (18.35 TWD). Highest evidence: Residual Income (76).
Notify me when 6242 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 21, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 48 · Market factors (momentum, volatility) 46
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Li Kang Biomedical Co., Ltd. manufactures and sells supplement, cosmeceutical, and hygienic drink products. It also engages in the management and consulting of tourism factory business; and offers telemarketing services. The company was formerly known as BAFO Technologies Corporation and changed its name to Li Kang Biomedical Co., Ltd. in September 2014.
Full company description
Li Kang Biomedical Co., Ltd. manufactures and sells supplement, cosmeceutical, and hygienic drink products. It also engages in the management and consulting of tourism factory business; and offers telemarketing services. The company was formerly known as BAFO Technologies Corporation and changed its name to Li Kang Biomedical Co., Ltd. in September 2014. Li Kang Biomedical Co., Ltd. was founded in 1982 and is based in Tainan City, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Li Kang Biomedical Co reported revenue of 589M TWD in FY2025 versus 387M TWD in FY2021, a compound +11.1%/yr. Reported net income was 83.8M TWD in FY2025, compounding +13.0%/yr from FY2021.
Watch 6242: get an alert when its fair value changes →
Peer Group
Travel Services · 90 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Travel Services median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Travel Services stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Booking Holdings BKNG | $182.80 | $152.94 | -16% |
| Airbnb, Inc ABNB | $148.62 | $57.47 | -61% |
| Royal Caribbean Cruises Ltd RCL | $286.96 | $215.19 | -25% |
| Viking Holdings VIK | $100.69 | $43.51 | -57% |
| Carnival Corporation CCL | $26.41 | $31.36 | +19% |
| Expedia Group EXPE | $268.77 | $248.63 | -7% |
| Trip.com Group TCOM | $42.45 | $88.82 | +109% |
| Norwegian Cruise Line Holdings NCLH | $19.46 | $20.28 | +4% |
| Global Business Travel Group GBTG | $9.40 | $4.17 | -56% |
| Travel + Leisure Co TNL | $73.27 | $27.29 | -63% |
Compare Li Kang Biomedical Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Consumer Cyclical stocks →
Frequently asked questions
Is Li Kang Biomedical Co (6242) overvalued or undervalued?
What is the fair value of 6242?
What is the quality score of 6242?
What is the revenue of Li Kang Biomedical Co (6242)?
What is the net profit margin of 6242?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Li Kang Biomedical Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.